InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,633.78
(
-0.13%
)

Replies to post #315 on Aptose Biosciences Inc (APTO)

Replies to #315 on Aptose Biosciences Inc (APTO)
icon url

dcaf7

03/29/23 12:30 PM

#316 RE: Tartiaboy #315

ADMIRAL trial was Gilteritinib against salvage therapy in r/r AML patients with Flt3 mutations. Several salvage regimens are available. I guess, they can be used as a control arm in Tusp mono trial.